Silo Pharma expands license agreement and patent portfolio

Silo enters into commercial evaluation license agreement for next generation liposomes

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials

Thermo Fisher Scientific collaborates with TransMIT to promote MSI platform

Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues

David Kendall named Zealand Pharma CMO

Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy

Ovensa and Celanese to collaborate to advance precision drug delivery

Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData

Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022

USFDA approves novel, dual-targeted treatment for type 2 diabetes

In clinical trials, treatment proved more effective than other therapies evaluated

Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022

Cipla has reported consolidated financial results for the period ended March 31, 2022

Pfizer to acquire Biohaven Pharmaceuticals for US $ 11.6 billion

Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need

TB4 shows potential as a combination treatment for diabetes-induced complications of the cornea

The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness